Navigation Links
Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
Date:12/17/2009

NASDAQ: CRME TSX: COM

VANCOUVER, Dec. 17 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that the recently-completed Phase 3 European Comparator Study (the AVRO study) evaluating vernakalant (iv) versus amiodarone for the acute conversion of atrial fibrillation met its primary endpoint.

The AVRO study achieved statistical significance in demonstrating the superiority of vernakalant (iv) over amiodarone in the conversion of atrial fibrillation to sinus rhythm within 90 minutes of the start of drug administration. Overall the data suggests that vernakalant (iv) was well-tolerated in the study population. There were no vernakalant-related deaths or cases of "Torsades de Pointes", a specific and well-characterized ventricular arrhythmia.

Cardiome expects that detailed results of this study will be presented at a scientific conference in 2010.

In April 2009, Cardiome and Merck & Co., Inc. announced a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation. The agreement provides a Merck affiliate, Merck Sharp & Dohme Corp., with exclusive global rights to vernakalant (oral) for the maintenance of normal heart rhythm in patients with atrial fibrillation, and provides another Merck affiliate, Merck Sharp & Dohme (Switzerland) GmbH, with exclusive rights outside of the United States, Canada and Mexico to vernakalant (iv) for rapid conversion of acute atrial fibrillation to normal heart rhythm. If approved by the European regulatory authorities, Merck has exclusive rights to commercialize vernakalant (iv) in the European Union.

'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome to Release Third Quarter Results
2. Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial
3. Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
4. Cardiome Pharma Corp. Announces Final Results of Tender Offer
5. Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer
6. Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
7. Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares
8. Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth
9. Cardiome to Hold Conference Call
10. Cardiome Announces Management Transition
11. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 T.E.N., a technology and ... today that William H. Murray, renowned author and ... Luminary Leadership Award winner. Presented annually, the ISE® ... outstanding leader and industry practitioner for his or ... the information security industry. , Formerly with IBM, ...
(Date:10/20/2014)... Los Angeles, CA (PRWEB) October 20, 2014 ... embodies fitness expertise, nutritional coaching, corporate wellness programming, authorship, ... MS, CPT, is excited to announce the release of ... , After many years of coaching thousands of ... pioneering nutrition tracking app that does not require calorie ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... Aliso Viejo, California (PRWEB) October 20, 2014 ... have announced the release of the Citrus theme for ... words I would use to describe the Citrus theme” Says ... been so easy to look so professional.” , Citrus comes ... . Included with the template are: four transitions for added ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... TeamPraxis, Hawaii,s premier physician management service organization (MSO) that ... Hawaii physicians, capped off its inaugural year of selling ... with seven new large client signings, bringing the first-year ... , , These sales completed a very successful ...
... ... , ... 2009 -- Talyst , a leader in pharmacy automation systems, found June to be ... was awarded as one of "Washington,s 100 Best Companies to Work For 2009" by Seattle ...
... MEDai, Inc. and Gold Standard, Inc., two Elsevier companies, ... medication therapy management (MTM) system that enables health plans, benefit ... Program requirements for 2010 and beyond for their Medicare Part ... to reporting and outcomes measurement. MTM 360 ...
... ... last year, blue sky scrubs has added new products and features, updated their content and ... ... has released a new version of their website, http://www.blueskyscrubs.com . Some of the ...
... ... for their HEPA-CARE® Air Filtration Systems and Germicidal UV Modules from healthcare facilities ... ... 2009 -- Abatement Technologies®, Inc. sees strong demand for their HEPA-CARE® Air Filtration ...
... Jesse ... delighted to announce ONRAD,s new web based PACS Application Service Provider (ASP) model. , ... Riverside, CA (PRWEB) July 9, 2009 ... (ONRAD) is delighted to announce ONRAD,s new web based PACS Application Service Provider (ASP) model. ...
Cached Medicine News:Health News:TeamPraxis Finishes Strong First Year of National Sales 2Health News:TeamPraxis Finishes Strong First Year of National Sales 3Health News:TeamPraxis Finishes Strong First Year of National Sales 4Health News:TeamPraxis Finishes Strong First Year of National Sales 5Health News:Talyst Receives Multiple Honors for Workplace Excellence 2Health News:Talyst Receives Multiple Honors for Workplace Excellence 3Health News:To Save Payors Time, Effort and Resources, MEDai and Gold Standard Collaborate on New CMS Medication Therapy Management Initiative 2Health News:To Save Payors Time, Effort and Resources, MEDai and Gold Standard Collaborate on New CMS Medication Therapy Management Initiative 3Health News:To Save Payors Time, Effort and Resources, MEDai and Gold Standard Collaborate on New CMS Medication Therapy Management Initiative 4Health News:Nursing Scrubs and Medical Scrubs Company blue sky scrubs Launches Enhanced Website 2Health News:Abatement Technologies Sees Strong Demand as Hospitals Prepare for Stage 6 Flu Pandemic 2Health News:Abatement Technologies Sees Strong Demand as Hospitals Prepare for Stage 6 Flu Pandemic 3Health News:ONRAD Announces New PACS Application Service Provider Model 2
(Date:10/17/2014)... , October 17, 2014 Investor-Edge ... Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 16, 2014, ended on a mixed ...
(Date:10/17/2014)... 17, 2014  UBM Medica US announces that ... and other clinicians who treat patients with type ... effective use of insulin .  Nearly ... replacement therapy – daily injections of one or ... in the function of pancreatic beta cells. Insulin is ...
(Date:10/17/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" ... biopharmaceutical company in China , ... from the China Food and Drug Administration (the ... concentrate ("PCC") at its Shandong Taibang facility. The ... facility for Good Manufacturing Practices ("GMP") compliance in ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... Incorporated,(Nasdaq: VPHM ) today announced that Michel de ... at the Acumen BioFin Rodman &,Renshaw 9th Annual Healthcare ... The conference is being held at the New York ... investors through, http://www.viropharma.com and available through November 20, ...
... Research,Associates, LLC announced today that it has ... Corporation (Amex: CVM ). The,full 56-page ... . CEL-SCI Corporation develops immune-based cancer ... is Multikine(R), a,next-generation, comprehensive immunotherapy that targets ...
Cached Medicine Technology:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation 3
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Medicine Products: